Secondary endpoint analyses from the trials showed 'significant improvements' in patients treated with the antibody.

"Amgen and AstraZeneca report results from Phase III trial of Tezspire for CRSwNP" was originally created and published by ...

Already billed as a potential blockbuster, Amgen and AstraZeneca’s Tezspire has turned in strong clinical data in chronic ...

The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for depemokimab for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps ...

in patients with severe disease who were still symptomatic despite standard care. The drugmaker is already carrying out a second phase 3 trial of Fasenra in CRSwNP – called ORCHID – which isn ...

(RTTNews) - GSK plc (GSK.L, GSK) announced that Depemokimab demonstrated clinically meaningful and statistically significant improvements for patients with chronic rhinosinusitis with nasal polyps ...

and systemic corticosteroid use in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) compared to placebo. 1,2 These data were published in the New England Journal of Medicine and ...

Chronic sinusitis with nasal polyps (CRSwNP) accounts for 20 to 33 percent ... significantly reducing the disease burden on nasal polyp patients. Many nasal polyp patients face the risk of ...

The U.S. Food and Drug Administration (FDA) has accepted GlaxoSmithKlines (NYSE:GSK) biologics license application for ...

there is a clear medical need for alternative treatment options to provide sustained symptom improvement and help alleviate the debilitating burden of this disease.” CRSwNP is a chronic ...

For the CRSwNP indication, the BLA includes data from ... to offer patients sustained inhibition of a key driver of their disease with just 2 doses per year.” A Prescription Drug User Fee ...